BioMaxima S.A. (WSE:BMX)

Market Cap	53.46M
Revenue (ttm)	57.05M
Net Income (ttm)	702.00K
Shares Out	4.19M
EPS (ttm)	0.17
PE Ratio	76.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,010
Average Volume	5,312
Open	12.75
Previous Close	12.90
Day's Range	12.20 - 12.95
52-Week Range	10.55 - 15.65
Beta	0.13
RSI	41.41
Earnings Date	Nov 30, 2025

About BioMaxima

BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and r...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 126
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BMX

Financial Performance

In 2024, BioMaxima's revenue was 52.85 million, an increase of 12.96% compared to the previous year's 46.79 million. Earnings were 535,000, a decrease of -8.70%.